Tatva Chintan Pharma Chem’s revenue and profitability missed our estimates significantly due to muted demand across business segments, lower price realization, and an increase in fixed costs.We believe short term pain will persist as Q3FY25E is expected to have similar performance; However, mid-term may improve gradually with a pick-up in global demand and commercialization of new products.